IL13 - interleukin 13 Gene
生物種: Canis lupus familiaris (sub-species: familiaris)
遺伝子タイプ: protein coding
遺伝子ID: 442990
About IL13
Primary_assembly 11: 21,744,389-21,747,315 forward strand.ROS_Cfam_1.0:CM025110.1
This gene has 1 transcript (splice variant) and 88 orthologues.
IL13 Products (2)
| mRNA | Protein | Name |
|---|---|---|
| NM_001003384.1 | NP_001003384.1 | interleukin-13 precursor |
| NM_001003384.1 | NP_001003384.1 | interleukin-13 precursor |
IL13 Protein Structure
IL13
IL13: pfam03487 (20 - 128)
- 0
- 100
- 131 a.a.
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
interleukin-13 |
|
Recombinant IL13 Proteins
| 製品番号 | 製品名 | アクセッション番号 | 純度 |
|---|---|---|---|
| HY-P78760 | IL-13 Protein, Canine (HEK293, His) | NP_001003384 (S19-R131) | ≥ 90%, as determined by reducing SDS-PAGE. |
Related Agents
- Approval
- Clinical Phase
- Pre-clinical Phase
Approval
阻害性抗体
(3)
| 製品番号 | 製品名 |
製品効果
|
純度 |
Rare Diseases
|
|---|---|---|---|---|
| HY-P9926 | Dupilumab | Inhibitor | ≥99.2% | Unkown |
| HY-P99025 | Lebrikizumab | Inhibitor | 99.90% | Unkown |
| HY-P99053 | Tralokinumab | Inhibitor | 99.12% | Unkown |
Clinical Phase
Bioactive Molecules
(2)
| 製品番号 | 製品名 |
製品効果
|
純度 |
Phase
|
|---|---|---|---|---|
| HY-154792 | Pyrrolidone carboxylic acid | / | Phase 4 | |
| HY-144683 | PF-07038124 | Inhibitor | / | Phase 2 |
阻害性抗体
(17)
| 製品番号 | 製品名 |
製品効果
|
純度 |
Phase
|
|---|---|---|---|---|
| HY-P990093 | Stapokibart | Inhibitor | 99.37% | Phase 4 |
| HY-P990748 | Lunsekimig | Inhibitor | 99.00% | Phase 3 |
| HY-P99496 | Cendakimab | Inhibitor | 99.96% | Phase 3 |
| HY-P990090 | Rademikibart | Inhibitor | 99.13% | Phase 3 |
| HY-P991515 | TQH-2722 | Inhibitor | / | Phase 3 |
| HY-P99870 | Eblasakimab | ≥99.0% | Phase 2 | |
| HY-P990741 | Galvokimig | 97.896% | Phase 2 | |
| HY-P991266 | SM-17 | Inhibitor | 96.98% | Phase 2 |
| HY-P99439 | Anrukinzumab | Inhibitor | 98.64% | Phase 2 |
| HY-P991729 | Zumilokibart | Inhibitor | 95.70% | Phase 2 |
| HY-P99883 | Romilkimab | Inhibitor | 99.01% | Phase 2 |
| HY-P99846 | Dectrekumab | / | Phase 2 | |
| HY-P990594 | GSK-679586 | Inhibitor | / | Phase 2 |
| HY-P991633 | TQC2938 | Inhibitor | / | Phase 2 |
| HY-P99417 | Abrezekimab | Inhibitor | 95.00% | Phase 1 |
| HY-P991258 | CNTO-5825 | 98.18% | Phase 1 | |
| HY-P990602 | IMA-026 | Inhibitor | / | Phase 1 |
Pre-clinical Phase
Bioactive Molecules
(44)
| 製品番号 | 製品名 |
製品効果
|
純度 |
Rare Diseases
|
|---|---|---|---|---|
| HY-126360 | Oxazolone | 98.0% | Unkown | |
| HY-P2797A | Chitinase, Streptomyces griseus | / | Unkown | |
| HY-N6013 | Aloin (mixture of A&B) | 99.36% | Unkown | |
| HY-P1848 | Pep-1 (uncapped) | 99.89% | Unkown | |
| HY-145551 | Atinvicitinib | Inhibitor | 98.62% | Unkown |
| HY-P2797 | Chitinase, Serratia marcescens | / | Unkown | |
| HY-144683A | PF-07038124 hydrochloride | Inhibitor | 99.26% | Unkown |
| HY-207120 | TSLP-IN-1 | Inhibitor | 99.67% | Unkown |
| HY-162248 | JAK1/2-IN-1 | Inhibitor | 98.36% | Unkown |
| HY-206870 | BP79 | Inhibitor | / | Unkown |
| HY-125019 | iJak-381 | Inhibitor | 99.86% | Unkown |
| HY-P11287A | DOTA-Pep-1L TFA | Ligand | 98.60% | Unkown |
| HY-110295 | SPL-334 | Inhibitor | 99.6% | Unkown |
| HY-158990 | GE1111 | 95.73% | Unkown | |
| HY-181006 | TSLP modulator-1 | Inhibitor | 99.61% | Unkown |
| HY-P10292 | NOTA-Pep-1L | 98.60% | Unkown | |
| HY-P11147 | IL13Rα2 D1 | Inhibitor | 99.17% | Unkown |
| HY-144684 | PDE4-IN-8 | Inhibitor | / | Unkown |
| HY-165484 | AVP-13358 | Inhibitor | / | Unkown |
| HY-172806 | PARP14 inhibitor 1 | Inhibitor | / | Unkown |
| HY-175650 | STAT6-IN-9 | Inhibitor | 98.11% | Unkown |
| HY-175876 | ADAM17-IN-1 | Inhibitor | / | Unkown |
| HY-183548 | XW-17 | Ligand | / | Unkown |
| HY-P11122 | MSP-1 P2 | Activator | / | Unkown |
| HY-P11287 | DOTA-Pep-1L | Ligand | / | Unkown |
| HY-P2797B | Chitinase | / | Unkown | |
| HY-P2797C | Chitinase,Trichoderma viride | / | Unkown | |
| HY-RS06685 | IL13 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS06686 | Il13 Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS06687 | Il13 Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS06688 | IL13RA1 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS06689 | IL13RA2 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-W109107 | GED 0507-34-Levo | / | Unkown | |
| HY-124613 | Pyrazinib | Inhibitor | / | Unkown |
| HY-174637 | Human IL13RA2 mRNA | / | Unkown | |
| HY-174638 | Human IL13RA1 mRNA | / | Unkown | |
| HY-174639 | Human IL13 mRNA | / | Unkown | |
| HY-187160 | IL-4-IN-2 | Inhibitor | / | Unkown |
| HY-N3989 | Haplopine | 99.49% | Unkown | |
| HY-N6013R | Aloin (mixture of A&B) (Standard) | / | Unkown | |
| HY-RS18438 | Il13ra2 Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS19279 | Il13ra1 Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS24920 | Il13ra2 Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS25769 | Il13ra1 Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
阻害性抗体
(9)
| 製品番号 | 製品名 |
製品効果
|
純度 |
Rare Diseases
|
|---|---|---|---|---|
| HY-P990121 | Anti-Mouse IL-4 Antibody (11B11) | Inhibitor | 97.67% | Unkown |
| HY-P991162 | Tilrekimig | Inhibitor | 97.00% | Unkown |
| HY-P990735 | Donzakimig | 98.67% | Unkown | |
| HY-P990699 | Riltovetbart | 99% | Unkown | |
| HY-P991150 | Ompekimig | Inhibitor | / | Unkown |
| HY-P992034 | APG808 | Inhibitor | / | Unkown |
| HY-P992132 | Solaprubart | Inhibitor | 99.59% | Unkown |
| HY-P990442 | Anti-IL-13 Antibody (CNTO 607) | Inhibitor | / | Unkown |
| HY-P991594 | Anti-IL-13 Antibody (C836) | Inhibitor | 97.20% | Unkown |
Compound Screening Libraries
Virtual Screening
Customize Your Library
Drug Screening Service